High pregnancy rates with administration of granulocyte colony-stimulating factor in ART-patients with repetitive implantation failure and lacking killer-cell immunglobulin-like receptors by Würfel, Wolfgang et al.
LETTERS TO THE EDITOR
High pregnancy rates with
administration of granulocyte
colony-stimulating factor in
ART-patients with repetitive
implantation failure and lacking
killer-cell immunglobulin-like
receptors
Sir,
As early as the year 2000, we reported on the use of granulocyte
colony-stimulating factor (G-CSF) for IVF patients who failed to
become pregnant after repeated embryo transfers (Wu ¨rfel, 2000;
Wu ¨rfel, 2003). At that time, we administered 300 mg of Molgramos-
tin in a single dose on the day of the embryo transfer. The preg-
nancy rate of patients treated with transfer on day 2 (average two
embryos) was almost 43% compared with almost 20% in the
placebo group.
The study by Scarpellini et al. (2009) now reports on continuous
administration of G-CSF, evidently without any identiﬁable negative
effects on the infants. Given this, we decided to run a pilot study
to investigate whether continuous administration of G-CSF to
patients with RIF (repetitive implantation failure) would be beneﬁcial
or not.
However, the initial criterion—patients’ failure to conceive after
repeated IVF or ICSI treatments—appeared to us to be too
vague. Taking the publication by Hiby et al. (2008) as a basis we
initially performed killer-cell immunglobulin-like receptor (KIR)
typing on patients with more than ﬁve unsuccessful IVF treatments
or embryo transfers. Only patients who lacked the three activating
receptors were accepted for the study; also included were patients
suffering from long-term unexplained sterility (average 6.8 years)
and lacking the three activating KIR genes. Groups overlapped to
some extent as cases of unexplained sterility had often undergone
(unsuccessful) IVF treatment.
The incidence of three lacking receptors (2 DS 1, 2 DS 3 and 3 DS
5) was very high in the group examined, at 78%. In addition, it was
noted that patients lacked not only the three named activating recep-
tors but also further receptors, so that in general the group was shown
to lack ﬁve to seven receptors including the above-mentioned three
activating receptors.
We performed IVF and ICSI treatment on the deﬁned group with
the target of a day 5 transfer. Patients received 13 million units of
Granocyte
TM (Lanogrostim) every 3 days in addition to the usual
luteal support. In cases where insufﬁcient numbers of fertilized
oocytes were available, the transfer was performed on day 2 (particu-
larly in cases of ovarian insufﬁciency).
Results for d + 5: Exclusively transfer of two blastocysts/morulae
or compacted morulae
Number of patients 40
Number of treatment cycles 42
Clinical pregnancies
(excluding biochemical) 31
of which abortions (clinical) 12
Pregnancy rate per treatment cycle/embryo transfer 73.8%
Abortion rate (clinical pregnancies) 38.7%
Results for transfer d + 2 (also including patients with signiﬁcant
ovarian insufﬁciency)
Number of patients 19
Number of treatment cycles 19
Clinical pregnancies 8
of which abortion (clinical) 3
Pregnancy rate per embryo transfer 42%
Abortion rate 37.5%
The group we selected and deﬁned certainly had a very poor prog-
nosis. The pregnancy rates achieved were extraordinarily high both in
the day 5 transfers and the day 2 transfers. However, the rate of clini-
cal abortions is also high (biochemical pregnancies were ignored). In
the meantime, we have also conducted a further pilot study in
which G-CSF was administered to patients with a history of multiple
unsuccessful IVF treatments or unexplained sterility, who had no
KIR defects. The results were very poor, with pregnancy rates cur-
rently below 10% per embryo transfer.
We conclude from this that the use of G-CSF is an extremely prom-
ising additional method of treatment in cases where defects in
materno-embryonic implantation communication can be shown. This
applies in particular to KIR defects and, in this, particularly to the
lack of the three activating receptors as described by Hiby et al.
Where such defects were not present, results of G-CSF treatment
were disappointing.
On the basis of the results of these pilot studies, we are currently
planning a prospective randomized double-blind study under the
initial criteria given above.
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Reply: High pregnancy rates with
administration of granulocyte
colony-stimulating factor in ART
patients with repetitive
implantation failure and lacking
killer-cell immunglobulin-like
receptors
Sir,
We read with very interest the letter of Prof. Wu ¨rfel et al., in which
they reported the data of their pilot study in the use of G-CSF in
ART patients with repetitive implantation failure and lacking killer-cell
immunglobulin-like receptors (KIR). They reported a high pregnancy
rate and concluded that G-CSF is an extremely promising additional
method of treatment in cases where defects in materno-embryonic
implantation communication can be shown.
This study is different from ours, since we treated women with
recurrent abortion and no patients with repetitive implantation
failure. Our study evidenced that the G-CSF is a promising treatment
in women with unexplained recurrent miscarriage: furthermore, our
study showed that this substance may increase the trophoblast
growth and metabolism since the elevated levels of beta-hCG
observed in these women during treatment. It is really interesting to
hear that also in ART patients the G-CSF may have a positive role
in increasing implantation rate and embryo growth. We have a
limited experience in the treatment of women with repetitive implan-
tation failure, and no experience at all for patients with lacking KIR.
However, in our few patients with repetitive implantation failure
treated with G-CSF, we observed similar results to the ones reported
by Dr Wu ¨rfel et al. Even though they are very preliminary results, we
encourage the authors of this pilot study to pursue in their study, since
we think that G-CSF may have a relevant role in promoting cell growth
in undifferentiated cells, such as it has been observed in stem cells and
may be a therapeutic tool in case of implantation failure. However,
we want to underline that in case of implantation failure, the
number of patients needed to reach statistical signiﬁcance are very
high, and consequently, multi-centre studies are warranted.
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The downstream effects of
vitamin D in spermatozoa needs
further study
Sir,
We are interested the article by Blomberg Jensen et al. (2010), where
the expression of vitamin D metabolic enzymes in reproductive
system of the male is described. In the discussion, the authors specu-
late that vitamin D regulates calcium ion concentration of spermato-
zoa. However, the following references do not support this
speculation. The concentration of calcium ion in semen plasma or
spermatozoa cytoplasm was not reported by Menegaz et al. (2009)
or Uhland et al. (1992). To our knowledge, the vitamin D regulation
of spermatozoa calcium ion channels or ionophores has not been
reported, and the prolonged survival of spermatozoa in low concen-
tration of vitamin D (Aquila et al., 2008) may not be mediated by
calcium ions. Although a positive effect of calcium ions on spermato-
genesis was proven by Almeida et al. (2000), the effect of calcium
on spermatozoa is complicated. The concentration of calcium ions
in cytoplasm of mature spermatozoa is negatively associated with
viability, but calcium inﬂow triggers the capacitation of spermatozoa
(Hong et al., 1984). The relative low concentration of calcium ions
is maintained by calcium ATPase on sperm membrane. Vitamin D
functions through several second messages (PKC, G-protein,
cAMP) in different cells; however, the downstream of vitamin D in
spermatozoa needs further study.
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